ASX Announcement

Results of Extraordinary General Meeting

Sydney, Australia, 19 August 2026: Imugene Limited (ASX:IMU) (Imugene, or the Company) is pleased to announce the results of today's Extraordinary General Meeting.

The results are set out in the attached document, in accordance with ASX Listing Rule 3.13.2 and Section 251AA(2) of the Corporation's Act. All resolutions were passed and decided by way of a poll.

Release approved by the Company Secretary on behalf of the Board.

End

For more information please contact:

General Investor Enquiries
shareholderenquiries@imugene.com

Media Enquiries
communications@imugene.com

Connect with us on LinkedIn @Imugene Limited
Watch us on YouTube @ImugeneLimited

About Imugene (ASX:IMU)

Imugene is a clinical stage cell therapy company developing an allogeneic CAR T for blood cancers. Our lead asset is an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. We are supported by a leading team of international cancer experts with extensive experience in developing novel cancer therapies.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and together with leading specialists and medical professionals, we believe Imugene's cellular therapy may become foundation treatments for cancer. Our goal is to ensure that Imugene is at the forefront of this rapidly growing global market.

Disclosure of Proxy Votes

Imugene Limited

Extraordinary General Meeting

Wednesday, 19 August 2026

Automic
GPO Box 5193, Sydney, NSW 2001
P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)
F +61 (0)2 8583 3040 E hello@automic.com.au
ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes				Poll Results (if applicable)			Results
Resolution	**Decided by Show of Hands (S) or Poll (P)**	**Total Number of Proxy Votes exercisable by proxies validly appointed**	**FOR**	**AGAINST**	**ABSTAIN**	**PROXY'S DISCRETION**	**FOR**	**AGAINST**	**ABSTAIN**	**OUTCOME**
1 Ratification of prior issue of First Tranche Placement Shares to Placement Subscribers	P	31,071,151	28,435,099 91.52%	2,351,425 7.57%	12,477,747	284,627 0.92%	29,098,667 92.52%	2,351,425 7.48%	12,477,747	Carried
2 Approval to issue Second Tranche Placement Shares to Placement Subscribers	P	42,812,404	40,147,647 93.78%	2,359,083 5.51%	736,494	305,674 0.71%	40,832,262 94.54%	2,359,083 5.46%	736,494	Carried
3 Approval to issue Placement Shares to Executive Director and Executive Chair – Paul Hopper	P	43,179,734	37,707,827 87.33%	5,249,093 12.16%	369,164	222,814 0.52%	38,309,582 87.95%	5,249,093 12.05%	369,164	Carried
4 Approval to issue Placement Shares to Chief Executive Officer and Managing Director - Leslie Chong	P	43,359,734	38,161,330 88.01%	4,971,471 11.47%	369,164	226,933 0.52%	38,767,204 88.63%	4,971,471 11.37%	369,164	Carried